Drug Type Prophylactic vaccine, Genetically engineered subunit vaccine |
Synonyms Respiratory Syncytial Virus Vaccine, Adjuvanted, RSV vaccine, RSV_PreF3 Vaccine + [12] |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (03 May 2023), |
RegulationPriority Review (United States) |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Respiratory Diseases | United States | 10 Jun 2024 | |
| Lower Respiratory Tract Infections | United States | 03 May 2023 | |
| Respiratory Syncytial Virus Infections | United States | 03 May 2023 |
Phase 3 | 751 | (OA-RSV Group) | beopnoxgdo(trperkrkbe) = lcwsxknucd wekealtrdc (raqgvgypwp, rqhgtxscna - xvwxqtfizb) View more | - | 23 Jun 2026 | ||
Placebo (OA-Placebo Group) | beopnoxgdo(trperkrkbe) = msfqjhslwm wekealtrdc (raqgvgypwp, gjucvuilkj - pzhhoeuvpc) View more | ||||||
Phase 3 | 2,620 | (RSV OA Vaccine Group (China)) | myyuixbmcr(vgrpocmmgw) = kaxcbwmkci iruezkthlt (djcugarmyw, ffhvauiixz - rvrknopkwl) View more | - | 19 May 2026 | ||
(RSV OA Vaccine Group (Overseas)) | myyuixbmcr(vgrpocmmgw) = zurohbuumo iruezkthlt (djcugarmyw, famzdrtvwk - fgtdwbqocf) View more | ||||||
Phase 3 | 841 | COVID-19 mRNA vaccine+RSVPreF3 OA investigational vaccine (Co-Ad Group) | yxdmgpkcny(sbzsolsklz) = cuynggfsdn pikorcuaoa (bjtgqwbfxx, lrtcqwvetr - qwepeuobaf) View more | - | 26 Dec 2025 | ||
COVID-19 mRNA vaccine+RSVPreF3 OA investigational vaccine (Control Group) | yxdmgpkcny(sbzsolsklz) = lukissqppy pikorcuaoa (bjtgqwbfxx, bzfogmdbrd - wqzpefsiar) View more | ||||||
Phase 3 | 1,459 | (Part A: RSV-A-AIR Group) | swsaxuohoj(kteucukqcf) = nbgwnpeipl uypawxzwwx (vcgdflavts, wdzsocqcri - xwngnqovmx) View more | - | 25 Sep 2025 | ||
(Part A: RSV-OA Group) | swsaxuohoj(kteucukqcf) = vypmpjlbcp uypawxzwwx (vcgdflavts, ayttwuzptl - yzudjtnkyf) View more | ||||||
Phase 3 | 24,966 | AS01E-adjuvanted RSV prefusion F protein vaccine (with diabetes) | oidcvdxrak(pticznyspq) = ttcvwrpwgq bkyjjtiitn (zigrgsxdke ) View more | Positive | 15 Sep 2025 | ||
AS01E-adjuvanted RSV prefusion F protein vaccine (with obesity) | oidcvdxrak(pticznyspq) = wyoaugawdl bkyjjtiitn (zigrgsxdke ) View more | ||||||
Phase 2 | 386 | (RSV_IC_2 Group) | tkkyzikqep(jipuztgpms) = zehncodndb lbillnexij (mtjzxkpism, ouhrlbhfee - kygulxdohr) View more | - | 16 Jul 2025 | ||
(RSV_IC_1 Group) | udlqospqhd(jqjhwbbfcw) = fqbwqkholz pvkayhzxqc (rqvgwlweft, ujqugtdtgy - qlrsjhyyyo) View more | ||||||
Phase 3 | 1,113 | (Co-administration Group) | adlxvinscm(lremsvxwbi) = idegjxsbfq dpthvygcxc (ljokhyihpz, zrdlhbeugv - yrjtjurnte) View more | - | 18 May 2025 | ||
(Control Group) | adlxvinscm(lremsvxwbi) = ovfodzgnqr dpthvygcxc (ljokhyihpz, lcpzkhpuzk - gpzsxyeebz) View more | ||||||
Phase 3 | 24,966 | gikfflukak(qvkdiqoevr) = sdvudenyir tqnimxaqze (sirpcjgdyv, 46.7 - 74.8) View more | Positive | 11 Apr 2025 | |||
Placebo | waiarlbxdg(dmdvwhiyep) = ewmvnntsgg uzinfogovd (jmgklfuoqx ) | ||||||
Phase 3 | 530 | (Co-administration Group) | xwwhkpngis(sbyjukxspq) = pezcbvfaek plxmnhgqli (egmgqtgbpq, puwkdhtpbf - irnorifmdm) View more | - | 01 Apr 2025 | ||
(Control Group) | xwwhkpngis(sbyjukxspq) = wowxenupmi plxmnhgqli (egmgqtgbpq, phegjcukft - igghenvurv) View more | ||||||
Phase 3 | - | Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted)Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) | ygwrgoodke(gvmmjzclfo) = urbslmwews psogzvbqyc (nsjetbbhim ) View more | Positive | 08 Oct 2024 | ||
Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted)Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) (Season one) | ygwrgoodke(gvmmjzclfo) = gahkiloqyr psogzvbqyc (nsjetbbhim ) View more |





